To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

NCT03220217 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastro-Enteropancreatic Neuroendocrine Tumor

Interventions

DRUG: Satoreotide trizoxetan 5-20μg
DRUG: Satoreotide trizoxetan 30-45μg

Sponsor

Ipsen